SynthesisEpidemiology and infection2017
A systematic review of varicella seroprevalence in European countries before universal childhood immunization: deriving incidence from seroprevalence data.
Synthesis in Epidemiology and infection, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Global herpes zoster burden in adults with COPD: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Varicella-zoster virus seroprevalence among reproductive-age women in Iran: a meta-analysis and implications for targeted immunization.BMC infectious diseases · 2025Pooled it
- Global herpes zoster burden in adults with asthma: a systematic review and meta-analysis.The European respiratory journal · 2024Pooled it
- Healthcare resource use and costs of varicella and its complications: A systematic literature review.Human vaccines & immunotherapeutics · 2023Pooled it
- Age-Dependent Risk of Respiratory Syncytial Virus Infection: A Systematic Review and Hazard Modeling From Serological Data.The Journal of infectious diseases · 2023Pooled it
- Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries.Human vaccines & immunotherapeutics · 2021Trial
- Trial
- Varicella zoster virus infection.Nature reviews. Disease primers · 2026Review
- Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission.The Indian journal of medical research · 2026Article
- Varicella epidemiology, susceptibility and cost burden in Chongqing China: implications for prevention and control strategies.BMC infectious diseases · 2026Article
- Human infection with pseudorabies virus: review of evidence, risk assessment, and future directions.Journal of virology · 2026Review
- Comorbidities in hospitalized patients with herpes zoster: an Italian retrospective observational study in the years 2011-2023.BMC infectious diseases · 2025Observational
- Perspectives on the History and Epidemiology of the Varicella Virus Vaccine and Future Challenges.Pathogens (Basel, Switzerland) · 2025Review
- Multi-proteomic profiling of the varicella-zoster virus-host interface reveals host susceptibilities to severe infection.Nature microbiology · 2025Article
- Seroprevalence of varicella zoster virus in Colombia: A community-based mixture models study.IJID regions · 2025Article
- Validating the Predictions of a Dynamic Transmission Model Using Real-World Data from a Universal Varicella Vaccination Program in Germany.Journal of market access & health policy · 2025Article
- Trends in public interest and vaccination coverage for Herpes Zoster.Public health in practice (Oxford, England) · 2025Article
- Review
- Varicella Zoster Virus Infection and Pregnancy: An Optimal Management Approach.Pathogens (Basel, Switzerland) · 2025Review
- Consensus Statements on Assessments and Vaccinations Prior to Commencement of Advanced Therapies for the Treatment of Inflammatory Bowel Diseases.Alimentary pharmacology & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Surveillance systems for varicella in Europe are highly heterogeneous or completely absent. We estimated the varicella incidence based on seroprevalence data, as these data are largely available and not biased by under-reporting or underascertainment. We conducted a systematic literature search for varicella serological data in Europe prior to introduction of universal varicella immunization. Age-specific serological data were pooled by country and serological profiles estimated using the catalytic model with piecewise constant force of infection. From the estimated profiles, we derived the annual incidence of varicella infection (/100·000) for six age groups (<5, 5-9, 10-14, 15-19, 20-39 and 40-65 years). In total, 43 studies from 16 countries were identified. By the age of 15 years, over 90% of the population has been infected by varicella in all countries except for Greece (86·6%) and Italy (85·3%). Substantial variability across countries exists in the age-specific annual incidence of varicella primary infection among the <5 years old (from 7052 to 16 122 per 100 000) and 5-9 years old (from 3292 to 11 798 per 100 000). The apparent validity and robustness of our estimates highlight the importance of serological data for the characterization of varicella epidemiology, even in the absence of sampling or assay standardization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.